ClearPoint Neuro (CLPT) Model Shift Triggers Bull Exit

A longtime ClearPoint Neuro (CLPT) bull sold his entire position, citing a shift in the company's business model that changes the original investment thesis.

The analyst, who had rated the stock a buy since January 2023, said the company is moving toward a capital equipment sales model, installing systems in hospitals. That shift replaces a steady stream of disposable revenue with lumpy, less predictable capital sales, he wrote in a Seeking Alpha article.

ClearPoint Neuro's transition from a recurring-revenue model to one dependent on hospital capital budgets creates uncertainty around revenue visibility and working capital, the analyst said. He exited the position reluctantly, acknowledging the stock's potential but preferring to avoid the near-term risk profile.

ClearPoint Neuro did not immediately respond to a request for comment.